Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$176.39 USD
+3.86 (2.24%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $174.39 -2.00 (-1.13%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
KRYS 176.39 +3.86(2.24%)
Will KRYS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for KRYS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KRYS
Are Options Traders Betting on a Big Move in Krystal Biotech (KRYS) Stock?
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know
KRYS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Krystal Biotech, Inc. (KRYS) to Report Q3 Results: Wall Street Expects Earnings Growth
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
All You Need to Know About Krystal Biotech (KRYS) Rating Upgrade to Buy
Other News for KRYS
Earnings To Watch: Krystal Biotech Inc (KRYS) Reports Q3 2024 Results
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
State Street Corp's Strategic Acquisition in Krystal Biotech Inc
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Stifel Nicolaus Remains a Buy on Krystal Biotech (KRYS)